IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000949
Publisher
BMJ
Online
2020-08-12
DOI
10.1136/jitc-2020-000949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Melanoma extracellular vesicles generate immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling
- (2019) Viktor Fleming et al. CANCER RESEARCH
- Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses
- (2019) Sarah Spencer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3
- (2019) Rosalinda Trovato et al. Journal for ImmunoTherapy of Cancer
- Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor
- (2019) Bao-Hua Li et al. MOLECULAR IMMUNOLOGY
- Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer
- (2018) Yoshikane Yamauchi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer
- (2018) Liu Yang et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
- (2018) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
- (2018) Viktor Fleming et al. Frontiers in Immunology
- Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model
- (2018) Jibin Li et al. MEDICAL SCIENCE MONITOR
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
- (2017) Ting-ting Wang et al. GUT
- CCR5 Directs the Mobilization of CD11b + Gr1 + Ly6C low Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development
- (2017) Elias Hawila et al. Cell Reports
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- Role of interleukin-6 in cancer progression and therapeutic resistance
- (2016) Neeraj Kumari et al. TUMOR BIOLOGY
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
- (2015) Jon Bjoern et al. OncoImmunology
- IL-6-stimulated CD11b+ CD14+ HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus
- (2015) Miao-Fen Chen et al. Oncotarget
- Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance
- (2014) Cheng Zhang et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The two faces of IL-6 in the tumor microenvironment
- (2014) Daniel T. Fisher et al. SEMINARS IN IMMUNOLOGY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
- (2013) Patrick L. Raber et al. INTERNATIONAL JOURNAL OF CANCER
- STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
- (2013) David Vasquez-Dunddel et al. JOURNAL OF CLINICAL INVESTIGATION
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Estimation of rat mammary tumor volume using caliper and ultrasonography measurements
- (2013) Ana Faustino-Rocha et al. LAB ANIMAL
- A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells
- (2012) Yan Zhang et al. CELL RESEARCH
- Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model
- (2011) C. Meyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
- (2010) Ilaria Marigo et al. IMMUNITY
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
- (2010) Thomas Condamine et al. TRENDS IN IMMUNOLOGY
- Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma
- (2009) F. Zhao et al. CLINICAL CANCER RESEARCH
- Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
- (2009) C. A. Corzo et al. JOURNAL OF IMMUNOLOGY
- Melanoma-Specific Memory T Cells Are Functionally Active in Ret Transgenic Mice without Macroscopic Tumors
- (2008) V. Umansky et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More